UBS Group’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.3M | Sell |
1,300,913
-345,465
| -21% | -$2.21M | ﹤0.01% | 3410 |
|
|
2026
Q1 | $9.55M | Buy |
1,646,378
+1,044,544
| +174% | +$6.93M | ﹤0.01% | 3408 |
|
|
2025
Q4 | $4.72M | Sell |
601,834
-1,180,900
| -66% | -$9.29M | ﹤0.01% | 4088 |
|
|
2025
Q3 | $14.5M | Buy |
1,782,734
+1,554,869
| +682% | +$10.3M | ﹤0.01% | 2912 |
|
|
2025
Q2 | $1.06M | Sell |
227,865
-635,911
| -74% | -$2.91M | ﹤0.01% | 5406 |
|
|
2025
Q1 | $4.74M | Sell |
863,776
-870,715
| -50% | -$3.51M | ﹤0.01% | 3832 |
|
|
2024
Q4 | $5.88M | Buy |
1,734,491
+1,451,239
| +512% | +$4.67M | ﹤0.01% | 3640 |
|
|
2024
Q3 | $807K | Buy |
283,252
+119,613
| +73% | +$307K | ﹤0.01% | 4839 |
|
|
2024
Q2 | $368K | Sell |
163,639
-32,974
| -17% | -$66.5K | ﹤0.01% | 5233 |
|
|
2024
Q1 | $435K | Buy |
196,613
+62,201
| +46% | +$161K | ﹤0.01% | 5308 |
|
|
2023
Q4 | $316K | Buy |
134,412
+59,972
| +81% | +$111K | ﹤0.01% | 5458 |
|
|
2023
Q3 | $138K | Buy |
74,440
+71,083
| +2,117% | +$163K | ﹤0.01% | 5626 |
|
|
2023
Q2 | $8.79K | Sell |
3,357
-44,463
| -93% | -$113K | ﹤0.01% | 7211 |
|
|
2023
Q1 | $77.9K | Buy |
47,820
+21,707
| +83% | +$27.2K | ﹤0.01% | 6116 |
|
|
2022
Q4 | $34.7K | Buy |
26,113
+11,065
| +74% | +$15.6K | ﹤0.01% | 7093 |
|
|
2022
Q3 | $23K | Buy |
15,048
+11,991
| +392% | +$19.8K | ﹤0.01% | 7219 |
|
|
2022
Q2 | $5K | Sell |
3,057
-47,294
| -94% | -$99.8K | ﹤0.01% | 8947 |
|
|
2022
Q1 | $129K | Buy |
50,351
+37,719
| +299% | +$92.1K | ﹤0.01% | 5707 |
|
|
2021
Q4 | $37K | Sell |
12,632
-13,900
| -52% | -$30K | ﹤0.01% | 7192 |
|
|
2021
Q3 | $65K | Buy |
26,532
+20,641
| +350% | +$59.9K | ﹤0.01% | 6124 |
|
|
2021
Q2 | $24K | Sell |
5,891
-210,940
| -97% | -$805K | ﹤0.01% | 7157 |
|
|
2021
Q1 | $978K | Buy |
216,831
+204,793
| +1,701% | +$1.1M | ﹤0.01% | 4269 |
|
|
2020
Q4 | $59K | Buy |
12,038
+3,959
| +49% | +$19.8K | ﹤0.01% | 6050 |
|
|
2020
Q3 | $48K | Sell |
8,079
-7,843
| -49% | -$31.4K | ﹤0.01% | 5685 |
|
|
2020
Q2 | $42K | Sell |
15,922
-13,922
| -47% | -$48.5K | ﹤0.01% | 6015 |
|
|
2020
Q1 | $58K | Sell |
29,844
-13,769
| -32% | -$59.2K | ﹤0.01% | 5708 |
|
|
2019
Q4 | $307K | Buy |
43,613
+15,461
| +55% | +$128K | ﹤0.01% | 5268 |
|
|
2019
Q3 | $277K | Buy |
28,152
+14,050
| +100% | +$158K | ﹤0.01% | 5009 |
|
|
2019
Q2 | $161K | Buy |
14,102
+4,706
| +50% | +$49.4K | ﹤0.01% | 5059 |
|
|
2019
Q1 | $94K | Hold |
9,396
| – | – | ﹤0.01% | 5112 |
|
|
2018
Q4 | $160K | Buy |
9,396
+7,072
| +304% | +$142K | ﹤0.01% | 5132 |
|
|
2018
Q3 | $41K | Buy |
2,324
+1,858
| +399% | +$40.3K | ﹤0.01% | 6307 |
|
|
2018
Q2 | $9K | Buy |
+466
| New | +$9.06K | ﹤0.01% | 7209 |
|
Other funds holding XERS
RA
UBS Group's XERS Position: Q2 2026 in Review
UBS Group reduced its Xeris Biopharma Holdings (XERS) stake by 21% in Q2 2026, selling an estimated $2.21M and leaving 1,300,913 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3410.
UBS Group first reported a position in XERS in Q2 2018 and has held it in 33 quarters since. The position peaked at $14.5M in Q3 2025. 239 funds tracked by Wall St. Rank hold XERS as of Q2 2026.
- UBS Group held 1,300,913 shares of Xeris Biopharma Holdings worth $10.3M as of Q2 2026.
- UBS Group sold 345,465 Xeris Biopharma Holdings shares in Q2 2026, an estimated $2.21M.
- Xeris Biopharma Holdings made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3410 holding.
- UBS Group first reported a position in Xeris Biopharma Holdings in Q2 2018 and has held it in 33 quarters since.
- UBS Group's Xeris Biopharma Holdings position peaked at $14.5M in Q3 2025.
- 239 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.